Eris Lifesciences Receives ANVISA approval at its Ahmedabad campus

Eris Lifesciences Limited, a leading Indian branded formulations manufacturing company, today announced that a manufacturing unit in its Ahmedabad campus has received approval from ANVISA, which is Brazil's national health regulatory agency. This approval follows a successful inspection conducted by the agency in May 2025 and enables Eris to enter Brazil, the largest pharmaceutical market in South America. A company spokesperson said that this approval by a stringent regulatory authority like ANVISA is a tangible endorsement of the GMP and quality systems at the Company's manufacturing facilities. The said manufacturing facility has been successfully inspected by various other regulatory agencies earlier in the year.

Shares of Eris Lifesciences Limited was last trading in BSE at Rs. 1768.90 as compared to the previous close of Rs. 1750.70. The total number of shares traded during the day was 1617 in over 328 trades.

The stock hit an intraday high of Rs. 1775.00 and intraday low of 1735.00. The net turnover during the day was Rs. 2829721.00.

Source : Equity Bulls

Keywords

ErisLifesciences INE406M01024 Pharmaceuticals ANVISA Brazil Approval Ahmedabad